Clearside Biomedical Inc (NASDAQ:CLSD)’s stock price rose 2.7% during mid-day trading on Wednesday . The company traded as high as $0.74 and last traded at $0.76, approximately 12,836 shares traded hands during mid-day trading. A decline of 99% from the average daily volume of 1,805,372 shares. The stock had previously closed at $0.74.

Several equities analysts have commented on the stock. Wedbush reissued a “buy” rating and set a $4.00 target price on shares of Clearside Biomedical in a research report on Tuesday, August 6th. Needham & Company LLC cut Clearside Biomedical from a “buy” rating to a “hold” rating in a research report on Friday, August 9th. Zacks Investment Research upgraded Clearside Biomedical from a “hold” rating to a “strong-buy” rating and set a $1.50 price target for the company in a research note on Monday, August 12th. ValuEngine raised Clearside Biomedical from a “sell” rating to a “hold” rating in a report on Thursday, August 1st. Finally, JMP Securities set a $3.00 price objective on Clearside Biomedical and gave the company a “buy” rating in a research note on Thursday, August 22nd. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating, three have given a buy rating and one has assigned a strong buy rating to the stock. Clearside Biomedical presently has a consensus rating of “Hold” and a consensus price target of $3.64.

The business’s 50 day moving average is $0.95 and its 200-day moving average is $1.16. The company has a debt-to-equity ratio of 0.69, a quick ratio of 3.47 and a current ratio of 3.47. The firm has a market capitalization of $25.49 million, a price-to-earnings ratio of -0.29 and a beta of -0.58.

Clearside Biomedical (NASDAQ:CLSD) last announced its earnings results on Wednesday, August 7th. The company reported ($0.15) EPS for the quarter, topping the consensus estimate of ($0.37) by $0.22. The firm had revenue of $0.05 million during the quarter, compared to the consensus estimate of $0.05 million. Equities research analysts forecast that Clearside Biomedical Inc will post -0.98 EPS for the current fiscal year.

Several institutional investors have recently bought and sold shares of the company. Geode Capital Management LLC lifted its position in shares of Clearside Biomedical by 4.9% during the 4th quarter. Geode Capital Management LLC now owns 303,512 shares of the company’s stock worth $324,000 after purchasing an additional 14,181 shares during the last quarter. Deutsche Bank AG increased its position in Clearside Biomedical by 487.2% in the 4th quarter. Deutsche Bank AG now owns 536,761 shares of the company’s stock worth $573,000 after buying an additional 445,346 shares during the period. SG Americas Securities LLC lifted its holdings in shares of Clearside Biomedical by 63.4% during the first quarter. SG Americas Securities LLC now owns 57,234 shares of the company’s stock worth $79,000 after buying an additional 22,213 shares during the last quarter. Parallel Advisors LLC acquired a new position in shares of Clearside Biomedical during the first quarter worth approximately $87,000. Finally, A.R.T. Advisors LLC acquired a new position in shares of Clearside Biomedical during the second quarter worth approximately $95,000. Institutional investors and hedge funds own 11.95% of the company’s stock.

Clearside Biomedical Company Profile (NASDAQ:CLSD)

Clearside Biomedical, Inc, a late-stage clinical biopharmaceutical company, develops pharmacological therapies to restore and preserve vision for people with serious eye diseases. It develops XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of macular edema associated with uveitis, diabetic macular edema, and macular edema associated with retinal vein occlusion.

Featured Story: Stock Symbol

Receive News & Ratings for Clearside Biomedical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clearside Biomedical and related companies with MarketBeat.com's FREE daily email newsletter.